The Detection of Circulating Tumor Cells (CTCs) in Breast Cancer With a Novel in Vivo Device

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03006055

Enrollment

190

Registered

2016-12-30

Start date

2016-04-30

Completion date

2016-12-31

Last updated

2017-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulating Tumor Cells.Breast

Brief summary

The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide which is CE approved. Application data of CellCollector in China is not available now. The purpose of this clinical trial is to confirm the validation and safety of CellCollector in Chinese patients.

Interventions

DEVICECirculating tumor cells

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Metastasis breast cancer confirmed with imaging examination * Have agreed to undergo CTC analysis in vivo; * ECOG：0-2

Exclusion criteria

* Non-metastasis breast cancer

Design outcomes

Primary

Measure	Time frame	Description
Validation of CellCollector	6 month	CTC enumeration and detection rate in Chinese patients with metastasis breast cancer will be analyzed by using CellCollector.
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	6 month	Number of participants with treatment-related adverse events and blood IgE level will be analyzed after CellCollector application.

Countries

China

Contacts

Primary ContactYH Dong, MD

dongyh_viroad@163.com+86031189928691

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026